Price
No data yet.
Social Signal Score
Revenue
$9.03M+367548.84%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Giorgio R. Saumat
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 77
- Beta
- 2.51
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 7.22
Financials
Revenue
$9.03M+367548.8%Net Income
$724.2K-78.3%EBITDA
$907.6K-73.1%Free Cash Flow
$665.7K+4237.5%EPS (diluted)
$0.00-96.0%Shares Outstanding (diluted)
290.00M+448.7%Operating Expenses
$2.03MCash & Debt
$2.82MReturn of Capital
$392.2KRevenue by Segment (annual)
$2.79MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $35.70M | $3.63M | $0.01 |
| 2024 | $33.12M | $3.25M | $0.01 |
| 2023 | $11.95M | $812.1K | $0.00 |
| 2022 | $48.5K | $-365.4K | $-0.00 |
| 2021 | $14.1K | $3.17M | $0.06 |
| 2020 | $140.9K | $-4.38M | $-0.09 |
| 2019 | $526.1K | $-1.54M | $-0.04 |
| 2018 | $770.6K | $-2.22M | $-0.04 |
| 2017 | $463.1K | $-1.74M | $-0.04 |
| 2016 | $428.2K | $-1.15M | $-0.03 |
| 2015 | $469.4K | $-1.22M | $-0.03 |
| 2014 | $80.3K | $-8.52M | $-0.23 |
| 2013 | $7.5K | $-39.8K | $-0.00 |
| 2012 | $41.9K | $-62.0K | $-0.01 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.02
- Implied price
- $0.13
- Return from $0.09
- 7.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.06 — -29.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 3 | 5 | 7 | 9 | 11 |
|---|---|---|---|---|---|
| -2.0% | -17.9% | -9.0% | -2.7% | 2.3% | 6.5% |
| 3.0% | -13.7% | -4.4% | 2.3% | 7.5% | 11.9% |
| 8.0% | -9.5% | 0.2% | 7.2% | 12.7% | 17.4% |
| 13.0% | -5.3% | 4.9% | 12.2% | 18.0% | 22.8% |
| 18.0% | -1.1% | 9.5% | 17.1% | 23.2% | 28.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
Earth Science Tech, Inc. (ETST) Acquires Zoolzy LLC to Drive Margin Expansion and Strategic Entry into the Veterinary Market MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified portfolio, today announced the acquisition of Zoolzy LLC, a Doral, Florida-based wholesale distributor of active pharmaceutical ingredients (APIs) and finished FDA-approved prescription products.
View source ↗
Earnings
Wed, Nov 11(in 3 months)
Typical surprise -35.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jun 18$0.01 vs $0.01beat
- Fri, Feb 13$0.00 vs $0.01miss
Estimates and results for ETST via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ETST officers and directors.
- Bought
- $747k
- Sold
- —
91 trades
0 trades
- Saumat Giorgio R.bought
- Saumat Giorgio R.bought
- Sanchez Yovan Arturobought
- Sanchez Yovan Arturobought
- Sanchez Yovan Arturobought
- Sanchez Yovan Arturobought
- Sanchez Yovan Arturobought
- Sanchez Yovan Arturobought
9 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.